IP Library Granted Patent US 12,270,085
Granted Patent B2
US 12,270,085 · App. 17/356,402 · Granted Apr 8, 2025

Method for detecting Chikungunya virus

Inventors: James M. Carrick (San Diego, CA); Jeffrey M. Linnen (Poway, CA)
Assignee: Gen-Probe Incorporated
C12Q1/701C12Q1/702Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,270,085
App. No.
17/356,402
Filed
Jun 23, 2021
Granted
Apr 8, 2025
Kind
B2
Art Unit
1681
USPC
506/9
Abstract

Compositions, methods and kits for detecting Chikungunya virus (CHIKV) nucleic acids are for detecting very low levels of the viral nucleic acids using nucleic acid amplification. The kit includes a first primer up to 100 bases long and includes a target-complementary 3′ terminal sequence of 15-48 contiguous bases. The first primer optionally may include a first primer 5′ sequence (i.e., an upstream sequence) that is not complementary to CHIKV nucleic acids.

Claims (32)

1. A method for determining whether a Chikungunya virus (CHIKV) nucleic acid sequence is present in a test sample comprising nucleic acids, said method comprising:

(a) contacting the nucleic acids of the test sample with a paired set of amplification primers, wherein

i) a first primer of the pair comprises a target-complementary 3′ terminal sequence complementary to at least 20 contiguous bases of nucleotides 35-74 of SEQ ID NO. 4, and

ii) a second primer of the pair comprises a target-complementary sequence complementary to an extension product of the first primer,

(b) performing an in vitro amplification reaction using the nucleic acids of the test sample as templates together with the set of primers, whereby, when the test sample comprises the CHIKV nucleic acid sequence, an amplification product is produced; and

(c) detecting any of the amplification product that is produced in the in vitro amplification reaction,

wherein said detecting of the amplification product in an amount greater than a cutoff value indicates that the CHIKV nucleic acid sequence is present in the test sample, and

wherein said detecting of the amplification product in an amount less than the cutoff value indicates that the CHIKV nucleic acid sequence is absent in the test sample.

2. The method of claim 1 , wherein either of the amplification primers optionally comprises a 5′ sequence that is not complementary to CHIKV.

3. The method of claim 1 , wherein the first primer includes a promoter sequence at its 5′ end.

4. The method of claim 3 , wherein the promotor sequence comprises SEQ ID NO. 90.

5. The method of claim 1 , wherein the target-complementary 3′ terminal sequence of the first primer is comprised in SEQ ID NO. 35.

6. The method of claim 1 , wherein a hybridization probe is used for the detection.

7. The method of claim 6 , wherein the hybridization probe comprises a target-complementary sequence in the range from 10 to 100 nucleotides.

8. The method of claim 7 , wherein the target-complementary sequence of the hybridization probe is comprised in SEQ ID NO. 74.

9. The method of claim 1 , wherein previous to step a), nucleic acids of the test sample are hybridized and captured with an oligonucleotide having a target-complementary sequence comprised in SEQ ID NO. 89 or in SEQ ID NO. 191.

10. The method of claim 1 , wherein a hybridization probe is used for detecting the amplification product, and the hybridization probe comprises a sequence of at least 10 nucleotides that are complementary to SEQ ID NO. 74.

11. The method of claim 1 , wherein the first primer comprises a 5′ terminal sequence that is not complementary to the CHKV nucleic acid sequence.

12. The method of claim 1 , wherein the first primer comprises a promoter primer sequence at its 5′ end, and the promoter primer sequence comprises SEQ ID NO. 115.

13. The method of claim 1 , wherein the target-complementary 3′ terminal sequence comprised in the first primer is complementary to at least 22 contiguous bases of nucleotides 35-74 of SEQ ID NO. 4.

14. The method of claim 1 , wherein the target-complementary 3′ terminal sequence comprised in the first primer is complementary to at least 25 contiguous bases of nucleotides 35-74 of SEQ ID NO. 4.

15. A kit for amplifying and detecting the Chikungunya virus (CHIKV) nucleic acid sequence in the method according to claim 1 , comprising:

i) the first primer comprising the target-complementary 3′ terminal sequence complementary to at least 20 contiguous bases of nucleotides 35-74 of SEQ ID NO. 4, and

ii) the second primer comprising the target-complementary terminal sequence complementary to the extension product of the first primer when SEQ ID NO. 4 is a template in a template-dependent primer extension reaction,

wherein the first primer further comprises a 5′ terminal sequence that is not complementary to the CHKV nucleic acid sequence.

16. The kit of claim 15 , further comprising at least one of:

(i) a hybridization probe comprising a target-complementary sequence in a range from 10 to 100 nucleotides comprised in SEQ ID NO. 74,

(ii) a capture oligonucleotide comprising a target-complementary sequence comprised in SEQ ID NO. 89 or in SEQ ID NO. 191.

17. An amplification primer comprising a target-complementary 3′ terminal sequence complementary to at least 20 contiguous bases of nucleotides 35-74 of SEQ ID NO. 4 and a 5′ sequence that is not complementary to CHIKV.

18. The amplification primer of claim 17 , further comprising a promoter sequence at its 5′ end.

19. The amplification primer of claim 18 , wherein the promotor sequence comprises SEQ ID NO. 90.

20. The amplification primer of claim 17 , wherein the target-complementary 3′ terminal sequence is comprised in SEQ ID NO. 35.

Assignments (3)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075926/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2025
From: CARRICK, JAMES M.; LINNEN, JEFFREY M.
To: GEN-PROBE INCORPORATED
Reel/Frame 070340/0641 →
Continuity (5)
Continuation 16430007 · Jun 3, 2019
Continuation 15054313 · Feb 26, 2016
Continuation 12386832 · Apr 21, 2009
Provisional Application 61046734 · Apr 21, 2008
Related Publication 20210324487A1 · Oct 21, 2021
References Cited (68)
US 5399491A · Kacian · 1995 [cited by examiner]
US 5952202A · Aoyagi et al. · 1999 [cited by applicant]
US 9273365B2 · Carrick et al. · 2016 [cited by applicant]
US 10344341B2 · Carrick et al. · 2019 [cited by applicant]
US 20020110810A1 · Shuber · 2002 [cited by applicant]
US 20040023207A1 · Polansky · 2004 [cited by applicant]
US 20040259108A1 · Linnen · 2004 [cited by examiner]
US 20060188912A1 · Gao · 2006 [cited by examiner]
US 20100055676A1 · Saito et al. · 2010 [cited by applicant]
CA 2721536A1 · 2009 [cited by applicant]
CN 101270394A · 2008 [cited by applicant]
EP 2281070B1 · 2015 [cited by applicant]
EP 2811037B1 · 2017 [cited by applicant]
EP 2808405B1 · 2018 [cited by applicant]
WO WO2007105111 · 2007 [cited by applicant]
WO WO2007130519 · 2007 [cited by applicant]
WO WO2008026225 · 2008 [cited by applicant]
WO WO2009044085 · 2009 [cited by applicant]
WO WO2009131683A3 · 2010 [cited by applicant]
Abd-Elsalam, “Bioinformatic tools and guideline for PCR primer design”, African Journal of Biotechnology, 2003, vol. 2(5), p. 91-95. [cited by applicant]
APO Patent Examination Report No. 1, European Patent Application No. 2009239586, Jan. 29, 2014. [cited by applicant]
Arankalle et al., “Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic”, Journal of General Virology, 2007, pp. 1967-1976, vol. 88, DOI 10.1099/vir.0… [cited by applicant]
CIPO Examination Report, Canadian Patent Application No. 2,721,536, Feb. 27, 2015. [cited by applicant]
Carletti et al., “Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay.”, The American Journal of Tropical Medicine and Hygiene Sep. 2007,… [cited by applicant]
Chan et al., “NASBA and Other Transcription-Based Amplification Methods for Research and Diagnostic Microbiology”, Reviews in Medical Microbiology, vol. 10, No. 4, pp. 185-196, Lippincott Williams & Wilkins, USA. [cited by applicant]
Database Genbank, Accesion AF369024, “Chikungunya virus strain S27-African prototype, complete genome”, Jan. 2003, 83(12):3075-3084. [cited by applicant]
Edwards et al., “Molecular diagnosis and analysis of Chikungunya virus”, J. Clin. Virol., 2007, 39:271-275, Elsevier Science, NL. [cited by applicant]
EPO Communication pursuant to Article 94(3) EPC, European Patent Application No. 09735119.1, Jul. 15, 2013. [cited by applicant]
EPO Communication pursuant to Article 94(3) EPC, European Patent Application No. 14175658.5, Oct. 14, 2016. [cited by applicant]
EPO Communication under Rule 71(3) EPC, European Patent Application No. 09735119.1, Aug. 4, 2014. [cited by applicant]
EPO Communication under Rule 71(3) EPC, European Patent Application No. 14175658.5, Oct. 14, 2016. [cited by applicant]
EPO Communication under Rule 71(3) EPC, European Patent Application No. 14175653.6, Nov. 2, 2016. [cited by applicant]
EPO Communication under Rule 71(3) EPC, European Patent Application No. 14175658.5, Dec. 13, 2017. [cited by applicant]
EPO extended European search report, European Patent Application No. 11417653.6, Nov. 10, 2014. [cited by applicant]
EPO extended European search report, European Patent Application No. 11417658.5, Nov. 5, 2014. [cited by applicant]
EPO extended European search report, European Patent Application No. 18174077.0, Jul. 4, 2018. [cited by applicant]
GenBank AM258993 [online] Jun. 4, 2006 [retrieved on Feb. 27, 2018] retrieved from https://www.ncbi.nlm.nih.gov/nuccore/106880543 (Year: 2006). [cited by applicant]
Grivard et al., “Molecular and serological diagnosis of Chikungunya virus infection”, Pathol Biol, 2007, 55:490-494, Elsevier, FR. [cited by applicant]
Hasebe et al., “Combined detection and genotyping of chikungunya virus by a specific reverse transcription-polymerase chain reaction”, J. Med. Virol., 2002, 67(3):370-374, Wiley-Liss, USA. [cited by applicant]
Ho, Phui San et al., “Establishment of one-step SYBR green-based real time-PCR assay for rapid detection and quantification of chikungunya virus infection”, Virology Journal, Jan. 21, 2010, vol. 7, No. 1, p. 13, Biomed … [cited by applicant]
JPO Official Action, Japanese Patent Application No. 2011-506292, Jan. 8, 2014. [cited by applicant]
Khan et al., “Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site,” J. Gen. Virol. 2002, 83:3075-3084, London Society For General Microbiology, UK. [cited by applicant]
Khan A H et al, “Chikungunya virus strain S27 prototype, complete genome”, Genbank Host—Genbank, Jan. 14, 2003. [cited by applicant]
Lanciotti et al. “Chikungunya Virus in US Travelers Returning from India”, 2006. Emerging Infectious Diseases 13(5):764-767. (Year: 2007). [cited by applicant]
Laurent et al., “Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus.”, Clinical Chemistry Aug. 2007, vol. 53, No. 8, pp. 1408-1414, Ame… [cited by applicant]
Lowe et al. Nucleic acid research, 1990, vol. 1897, p. 1757-1761. [cited by applicant]
E Nakouné et al., “The Chikungunya virus”, Annales de biologie clinique, France, Jul. 1, 2007, pp. 349-356, URL: http://www.ncbi.nlm.nih.gov/pubmed/17627914, (Oct. 22, 2014). [cited by applicant]
Nucleic acid sequence search reports (AC AOJ21252, AOJ21293, AOJ21291). [cited by applicant]
Notice of Reasons for Rejection, Japanese Patent Application No. 2011-506292, mailed Jan. 8, 2014. [cited by applicant]
PCT International Preliminary Report on Patentability, PCT Patent Application No. PCT/US2009/002504, Oct. 26, 2010. [cited by applicant]
PCT Search Report and Written Opinion, PCT Patent Application No. PCT/US2009/002504, Dec. 3, 2010. [cited by applicant]
Patent Examination Report, Australian Patent Application No. 2009238586, issued Jan. 29, 2014. [cited by applicant]
Parida, M M et al., “Rapid and real-time detection of Chikungunya virus by reverse transcription loop-mediated isothermal amplification assay.”, Journal of Clinical Microbiology Feb. 2007, vol. 45, No. 2, pp. 351-357, A… [cited by applicant]
Parola et al. “Novel Chikungunya Virus Variant in Travelers Returning from Indian Ocean Islands”, Emerging Infectious Diseases, Oct. 2006, pp. 1493-1499, vol. 12, No. 10, www.cdc.gov/eid. [cited by applicant]
Pastorino et al., “Development of a TaqMan® RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses”, Journal of Virological Methods, 2005, vol. 124, No. 1, pp. 65-71… [cited by applicant]
Pfeffer et al., “Specific detection of chikungunya virus using a RT-PCR/nested PCR combination.”, Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health Feb. 2002, vol. 49, No. 1, pp. 49-54,… [cited by applicant]
Rezza et al., “Infection with Chikungunya virus in Italy: an outbreak in a temperate region”, The Lancet, 2007, 370:1805-1846, Lancet Publishing Group, USA. [cited by applicant]
Requisition by the Examiner, Canadian Patent Application No. 2,721,536, dated Feb. 27, 2015. [cited by applicant]
Santhosh et al., “Development and evaluation of SYBR Green I-based one-step real-time RT-PCT assay for detection and quantification of Chinkungunya virus”, J. Clin, Virol., 2007, 39:188-193, Elsevier Science, NL. [cited by applicant]
Santhosh et al., “Comparative full genome analysis revealed E1:A226V shift in 2007 Indian Chikungunya virus isolates”, Virus Research, Apr. 1, 2008, vol. 135, pp. 36-41 http://dx.doi.org/10.1016/j.viruses.2008.02.004, E… [cited by applicant]
Schuffenecker et al., “Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak.”, PLOS Medicine Jul. 2006, vol. 3, No. 7, pp. 1058-1071, Public Library of Science, USA. [cited by applicant]
USPTO Non-Final Rejection, U.S. Appl. No. 12/386,832, Nov. 21, 2011. [cited by applicant]
USPTO Final Rejection, U.S. Appl. No. 12/386,832, Jul. 20, 2012. [cited by applicant]
USPTO Non-Final Rejection, U.S. Appl. No. 12/386,832, May 7, 2013. [cited by applicant]
USPTO Non-Final Rejection, U.S. Appl. No. 12/386,832, Nov. 22, 2013. [cited by applicant]
USPTO Final Rejection, U.S. Appl. No. 12/386,832, Jul. 8, 2014. [cited by applicant]
USPTO Notice of Allowance, U.S. Appl. No. 12/386,832, Jul. 8, 2014. [cited by applicant]
Office Action issued in Canadian Application No. 3128538, dated Nov. 8, 2022. [cited by applicant]